Vital Capital Medical - Temple TX DST is a single-tenant, net-leased healthcare Delaware Statutory Trust holding the Temple Rehabilitation Hospital, a 36-bed inpatient rehabilitation facility of approximately 38,817 SF on a ~6-acre site at 23621 SE H K Dodgen, Temple, Texas (Killeen-Temple MSA, on the I-35 corridor between Austin and Waco). Built in 2018, the purpose-built hospital treats stroke, brain-injury, neurological, orthopedic, and cardiac rehabilitation patients. The Trust master-leases the Property to a Sponsor-affiliate Master Tenant, which has assumed an absolute-net sublease to the operating tenant, CRH of Temple, LLC, an unaffiliated operator whose parent is Lifepoint Health (rated B by S&P and B2 by Moody's), with roughly 7.5 years of term remaining and three 5-year extension options. The Trust acquired the Property on November 25, 2025 from Community Healthcare Trust (CHCT Texas, LLC) for a $29,695,000 purchase price (against a $29,750,000 CBRE appraisal), capitalized within a $34,551,889 total investment cost of $15,958,139 equity and an $18,593,750 First Horizon Bank loan (5.65% effective fixed via swap; seven-year term maturing November 2032; interest-only for four years then 25-year amortization), a 53.81% loan-to-cost. The forecast targets a 7.32% Year-1 cash-on-cash building to 7.91% by Year 4 before amortization begins, averaging 7.28% over a seven-year hold, with a discretionary 721 UPREIT exit.
Projected annual cash-on-cash distributions with the corresponding tax-equivalent yield over the hold, based on the sponsor’s underwriting assumptions.
Illustrative projections only — targeted distributions are not guaranteed and actual results will vary. Tax-equivalent yield assumes depreciation shelter of distributed income.
This is a yield-oriented, single-tenant healthcare net-lease investment whose roughly 7.3% projected return is best understood as compensation for concentrated operator-credit risk rather than as a low-risk coupon: the rent ultimately depends on a single inpatient-rehabilitation operator backed by speculative-grade Lifepoint Health, in a purpose-built facility with little alternative use. The risk-adjusted profile turns on two linked questions, the operator's multi-year solvency and reimbursement stability, and the terminal value of a short-dated, special-purpose medical asset whose ~7.5-year remaining lease roughly coincides with the seven-year hold, so the exit is essentially a bet on renewal or on a buyer accepting re-leasing risk. The financing is conservative on its face (53.81% loan-to-cost, a 2.24x early DSCR, a swapped 5.65% fixed rate), but the four-year interest-only period flatters the early years and the November 2032 maturity coincides with disposition, while the bridge-equity takeout and master-lease layering add structural and conflict considerations. For an investor seeking higher current income from healthcare real estate and comfortable with single-operator, single-asset concentration and below-investment-grade credit, the offering is internally coherent; the operator-credit quality, the lease-versus-hold term match, and the specialized residual value are the idiosyncratic items least reflected in the headline yield.
The offering delivers an above-average projected income stream (7.32% Year-1 cash-on-cash building to 7.91% by Year 4, averaging 7.28% over the seven-year hold) from a modern, 2018-built, 100%-leased inpatient rehabilitation hospital on an absolute-net lease, with the operating tenant responsible for taxes, insurance, and maintenance and holding three 5-year renewal options. The asset sits in the Temple Medical District along the high-traffic I-35 corridor within the growing Killeen-Temple MSA, a genuine regional healthcare hub, and was acquired at essentially its appraised value with moderate leverage (53.81% loan-to-cost) on a 5.65% swapped fixed-rate loan that is interest-only for four years, supporting a strong early DSCR of 2.24x. A discretionary 721 UPREIT exit offers a potential pathway to REIT-unit liquidity and diversification.
The income rests on a single operator of a single special-purpose asset, and the operator's parent, Lifepoint Health, carries speculative-grade ratings (B/B2), so the elevated yield is materially a credit-risk premium and a Lifepoint or operating-tenant distress event would directly threaten the rent. The 36-bed inpatient rehabilitation hospital is a highly specialized facility with limited alternative use, creating substantial re-leasing cost and downtime risk, and with only ~7.5 years of remaining lease term against a seven-year hold the planned exit coincides with significant term burn-off, leaving terminal value dependent on a renewal or a buyer willing to underwrite short-dated single-tenant medical risk. The structure interposes a Sponsor-affiliate master tenant between the Trust and the third-party operating tenant and was funded in part by roughly $11.5 million of Sponsor and MBRE preferred bridge equity redeemed by offering proceeds, importing bridge-carry cost, reliance on full syndication, and affiliate conflicts. Leverage of 53.81% loan-to-cost amortizes after a four-year interest-only period, stepping the cash-on-cash down from 7.91% in Year 4 to 6.63% in Year 5, and the loan matures in November 2032 concurrent with the hold, concentrating refinancing or forced-sale risk; healthcare reimbursement and regulatory shifts affecting inpatient-rehab economics are an additional exogenous risk to the operator's rent coverage.
Financing terms for this offering are summarized below.
| Metric | This Offering | Benchmark | Difference |
|---|---|---|---|
| Average Yield | 7.28% | 6.41% | +13.57% |
| Max Yield | 7.91% | 7.03% | +12.52% |
| 10-Yr Income Growth | 8.06% | 15.43% | −47.76% |
Benchmark reflects the average of comparable Healthcare offerings. Differences are relative to the benchmark.
Offering Documents Available By Request
HPA Exchange is the DST platform affiliated with Housing Partnership Acquisitions, specializing in single-family rental (SFR) portfolios—an institutionalizing asset class that brings scaled residential operations to exchange investors. Its differentiation is the SFR focus and the operating platform behind it; current AUM is not publicly disclosed, and the firm's limited public footprint warrants direct diligence.
This page describes a specific Delaware Statutory Trust offering (Vital Capital Medical - Temple TX DST) and is provided for informational purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy any security. Any offering is made solely to verified accredited investors and only by means of a confidential private placement memorandum (PPM).
All figures shown — including minimum investment, cash-flow projections, tax-equivalent yield, loan-to-value, and hold period — reflect the sponsor's current estimates and assumptions and are not guarantees of future performance. Tax-equivalent yield depends on each investor's tax circumstances; projected distributions may not be achieved and actual results will vary. Sponsor track record, benchmark data, and full-cycle averages describe prior programs and are not indicative of the results of this offering.
An investment in a DST is speculative, illiquid, and involves a high degree of risk, including the possible loss of the entire amount invested. There is no public market for these interests, distributions are not guaranteed, and investors have no control over property operations. 1031 exchange and tax treatment depend on each investor's individual circumstances and on tax laws that are subject to change; consult your own tax and legal advisors.
Tax-equivalent yield represents the pre-tax yield a fully taxable investment would need to generate in order to match the after-tax cash flow of this offering. It assumes that a portion of distributions is sheltered by depreciation and other deductions, and it depends entirely on each investor's individual tax bracket, state of residence, and holding structure. It is illustrative only and is not a projection of return. Cap rate equivalent is the implied capitalization rate (net operating income divided by purchase price) shown solely for comparison to direct real estate; it is not a distribution rate, a yield, or a measure of investor return.
This offering and all terms shown are subject to change, withdrawal, or cancellation at any time without notice, and availability is not guaranteed. Nothing on this page creates a commitment or reservation. An investment is confirmed only upon the sponsor's acceptance of fully executed subscription documents; no other communication, indication of interest, or reservation constitutes a binding investment.